XML 56 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
DIVESTITURES - Narrative (Details)
$ in Millions
2 Months Ended 3 Months Ended 9 Months Ended
Nov. 06, 2017
Sep. 29, 2017
USD ($)
Jun. 28, 2017
USD ($)
Mar. 03, 2017
USD ($)
Dec. 31, 2017
Dec. 31, 2017
USD ($)
Sep. 30, 2017
USD ($)
country
Jun. 30, 2017
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2017
USD ($)
country
Sep. 30, 2016
USD ($)
Nov. 07, 2017
USD ($)
Dec. 31, 2016
USD ($)
Nov. 02, 2016
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Number of countries in which entity markets (more than 15 countries) | country             100     100        
Sprout Pharmaceuticals, Inc. | Minimum                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Purchase obligation                           $ 200
Scenario, Forecast | Subsequent Event | Sprout Pharmaceuticals, Inc.                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Loan term 5 years       5 years                  
Related party loan                       $ 25    
Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Impairment of long-lived assets                   $ 115        
Liabilities held for sale             $ 461     461        
Deferred tax liabilities             293     293     $ 57  
Contingent consideration             168     168        
Other liabilities                         $ 57  
CeraVe, AcneFree, and AMBI Skincare Brands                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Gain on sale of business             (3)   $ 0 316 $ 0      
CeraVe, AcneFree, and AMBI Skincare Brands | Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Cash consideration       $ 1,300                    
Gain on sale of business                   316        
Dendreon Sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Gain on sale of business             25   0 98 0      
Dendreon Sale | Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Cash consideration     $ 820                      
Gain on sale of business               $ 73   98        
Consideration             845     845        
iNova                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Gain on sale of business             $ 306   $ 0 $ 306 $ 0      
iNova | Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Cash consideration   $ 938                        
Gain on sale of business   $ 306                        
Number of countries in which entity markets (more than 15 countries) | country             15     15        
Obagi | Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Impairment of finite-lived intangible assets                   $ 103        
Net assets and liabilities             $ 187     187        
Obagi | Held-for-sale | Scenario, Forecast                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Cash consideration           $ 190                
Sprout Pharmaceuticals, Inc. | Held-for-sale                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Net assets and liabilities             $ 71     71        
Impairment of long-lived assets                   $ 352        
Sprout Pharmaceuticals, Inc. | Disposed of by Sale | Scenario, Forecast | Subsequent Event                            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                            
Royalty percentage         6.00%